SGLT2 inhibitor for brain protection after stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether an SGLT2 inhibitor (a diabetes medicine) can protect the brain after a recent moderate-to-severe ischemic stroke. It may help reduce damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a clot-type stroke (ischemic stroke) in the last 3 days.
- Your stroke is moderate to severe, with a NIHSS score between 4 and 25.
- You are 18 years or older.
- You have not used an SGLT2 inhibitor (like Jardiance) in the past 4 weeks.
- You do not have severe kidney or liver problems, type 1 diabetes, or a body mass index below 18.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine (a GLP-1 receptor agonist) given along with the standard clot-removal procedure for people who have had a severe stroke from a large blockage. The goal is to see if the medicine helps improve recovery by protecting the brain.
This trial is for people who have had a specific type of stroke (acute ischemic stroke with a large blocked vessel) and are already scheduled for a procedure to remove the clot (mechanical thrombectomy). The study will test whether giving an SGLT2 inhibitor (a diabetes medicine that also helps the heart and kidneys) before the procedure improves recovery.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial tests whether a type 2 diabetes medicine called a DPP4 inhibitor can help prevent memory and thinking problems after a mild stroke. It is for people with recent stroke and well-controlled diabetes.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.